The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer
Open accessAbstract
Purpose: To develop a guideline to improve the accuracy of human epidermal growth factor receptor 2 (HER2) testing in invasive breast cancer and its utility as a predictive marker. Methods: The American Society of Clinical Oncology and the College of American Pathologists convened an expert panel, which conducted a systematic review of the literature and developed recommendations for optimal HER2 testing performance. The guideline was reviewed by selected experts and approved by the board of directors for both organizations. Results: Approximately 20% of current HER2 testing may be inaccurate. When carefully validated testing is performed, available data do not clearly demonstrate the superiority of either immunohistochemistry (IHC) or in situ hybridization (ISH) as a predictor of benefit from anti-HER2 therapy. Recommendations: The panel recommends that HER2 status should be determined for all invasive breast cancer. A testing algorithm that relies on accurate, reproducible assay performance, including newly available types of brightfield ISH, is proposed. Elements to reliably reduce assay variation (for example, specimen handling, assay exclusion, and reporting criteria) are specified. An algorithm defining positive, equivocal, and negative values for both HER2 protein expression and gene amplification is recommended: a positive HER2 result is IHC staining of 3+ (uniform, intense membrane staining of > 30% of invasive tumor cells), a fluorescent in situ hybridization (FISH) result of more than six HER2 gene copies per nucleus or a FISH ratio (HER2 gene signals to chromosome 17 signals) of more than 2.2; a negative result is an IHC staining of 0 or 1+, a FISH result of less than 4.0 HER2 gene copies per nucleus, or FISH ratio of less than 1.8. Equivocal results require additional action for final determination. It is recommended that to perform HER2 testing, laboratories show 95% concordance with another validated test for positive and negative assay values. The panel strongly recommends validation of laboratory assay or modifications, use of standardized operating procedures, and compliance with new testing criteria to be monitored with the use of stringent laboratory accreditation standards, proficiency testing, and competency assessment. The panel recommends that HER2 testing be done in a CAP-accredited laboratory or in a laboratory that meets the accreditation and proficiency testing requirements set out by this document.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Self-citationStudies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,816
Self-citationTrastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,356
Self-citationTrastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052306 · Cited by 5,084
Self-citationCobleigh, M. A., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,765
Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.719 · Cited by 1,860
Self-citationAdjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer
Joensuu, H., Kellokumpu-Lehtinen, P.-L., Bono, P., Alanko, T., Kataja, V., Asola, R., Utriainen, T., Kokko, R., Hemminki, A., Tarkkanen, M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053028 · Cited by 1,403
Ellis, M. J., Coop, A., Singh, B., Mauriac, L., Llombert-Cussac, A., Jänicke, F., Miller, W. R., Evans, D. B., Dugan, M., Brady, C., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.18.3808 · Cited by 1,060
Prognostic Factors in Breast Cancer: College of American Pathologists Consensus Statement 1999
Fitzgibbons, P. L., Page, D. L., Weaver, D., Thor, A. D., Allred, D. C., Clark, G. M., Ruby, S. G., O'Malley, F., Simpson, J. F., Connolly, J. L., et al. (2000) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2000-124-0966-pfibc · Cited by 1,016
Self-citationBast, R. C., Ravdin, P., Hayes, D. F., Bates, S., Fritsche, H., Jessup, J. M., Kemeny, N., Locker, G. Y., Mennel, R. G., & Somerfield, M. R. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.6.1865 · Cited by 879
Self-citationTan-Chiu, E., Yothers, G., Romond, E., Geyer, C. E., Ewer, M., Keefe, D., Shannon, R. P., Swain, S. M., Brown, A., Fehrenbacher, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.4091 · Cited by 808
Press, M. F., Bernstein, L., Thomas, P. A., Meisner, L. F., Zhou, J. Y., Ma, Y., Hung, G., Robinson, R. A., Harris, C., El-Naggar, A., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.8.2894 · Cited by 802
Self-citationAkiyama, T., Sudo, C., Ogawara, H., Toyoshima, K., & Yamamoto, T. (1986) · Science · doi:10.1126/science.3012781 · Cited by 796
Owens, M. A., Horten, B. C., & Da Silva, M. M. (2004) · Clinical Breast Cancer · doi:10.3816/cbc.2004.n.011 · Cited by 657
erbB-2, p53, and Efficacy of Adjuvant Therapy in Lymph Node-Positive Breast Cancer
Thor, A. D., Berry, D. A., Budman, D. R., Muss, H. B., Kute, T., Henderson, I. C., Barcos, M., Cirrincione, C., Edgerton, S., Allred, C., et al. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.18.1346 · Cited by 612
Konecny, G., Pauletti, G., Pegram, M., Untch, M., Dandekar, S., Aguilar, Z., Wilson, C., Rong, H.-M., Bauerfeind, I., Felber, M., et al. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.2.142 · Cited by 588
Self-citationHER2 and Responsiveness of Breast Cancer to Adjuvant Chemotherapy
Pritchard, K. I., Shepherd, L. E., O'Malley, F. P., Andrulis, I. L., Tu, D., Bramwell, V. H., & Levine, M. N. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054504 · Cited by 509
Paik, S., Bryant, J., Tan-Chiu, E., Romond, E., Hiller, W., Park, K., Brown, A., Yothers, G., Anderson, S., Smith, R., et al. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.11.852 · Cited by 484
Self-citationAllred, D. C., Clark, G. M., Tandon, A. K., Molina, R., Tormey, D. C., Osborne, C. K., Gilchrist, K. W., Mansour, E. G., Abeloff, M., & Eudey, L. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.4.599 · Cited by 456
Self-citationHER-2 Testing in Breast Cancer Using Parallel Tissue-Based Methods
Yaziji, H. (2004) · JAMA · doi:10.1001/jama.291.16.1972 · Cited by 438
Perez, E. A., Suman, V. J., Davidson, N. E., Martino, S., Kaufman, P. A., Lingle, W. L., Flynn, P. J., Ingle, J. N., Visscher, D., & Jenkins, R. B. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.4744 · Cited by 438
Self-citationPress, M. F., Pike, M. C., Chazin, V. R., Hung, G., Udove, J. A., Markowicz, M., Danyluk, J., Godolphin, W. J., Sliwkowski, M. X., & Akita, R. W. (1993) · PubMed · Cited by 426
Self-citationPress, M. F., Slamon, D. J., Flom, K. J., Park, J., Zhou, J.-Y., & Bernstein, L. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.09.094 · Cited by 391
Self-citationConcordance Between Local and Central Laboratory HER2 Testing in the Breast Intergroup Trial N9831
Roche, P. C., Suman, V. J., Jenkins, R. B., Davidson, N. E., Martino, S., Kaufman, P. A., Addo, F. K., Murphy, B., Ingle, J. N., & Perez, E. A. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.11.855 · Cited by 390
Self-citationMass, R. D., Press, M. F., Anderson, S., Cobleigh, M. A., Vogel, C. L., Dybdal, N., Leiberman, G., & Slamon, D. J. (2005) · Clinical Breast Cancer · doi:10.3816/cbc.2005.n.026 · Cited by 359
Self-citationPress, M. F., Sauter, G., Bernstein, L., Villalobos, I. E., Mirlacher, M., Zhou, J.-Y., Wardeh, R., Li, Y.-T., Guzman, R., Ma, Y., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0636 · Cited by 311
Self-citationYamauchi, H., Stearns, V., & Hayes, D. F. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.8.2334 · Cited by 291
Self-citationPatterns of HER-2/neu Amplification and Overexpression in Primary and Metastatic Breast Cancer
Simon, R., Nocito, A., Hubscher, T., Bucher, C., Torhorst, J., Schraml, P., Bubendorf, L., Mihatsch, M. M., Moch, H., Wilber, K., et al. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.15.1141 · Cited by 290
Current Perspectives on HER2 Testing: A Review of National Testing Guidelines
Bilous, M., Dowsett, M., Hanna, W., Isola, J., Lebeau, A., Moreno, A., Penault-Llorca, F., Rüschoff, J., Tomasic, G., & van de Vijver, M. (2003) · Modern Pathology · doi:10.1097/01.mp.0000052102.90815.82 · Cited by 264
Self-citationEvaluating HER2 amplification and overexpression in breast cancer
Bartlett, J. M. S., Going, J. J., Mallon, E. A., Watters, A. D., Reeves, J. R., Stanton, P., Richmond, J., Donald, B., Ferrier, R., & Cooke, T. G. (2001) · The Journal of Pathology · doi:10.1002/path.971 · Cited by 242
Dowsett, M., Bartlett, J., Ellis, I., Salter, J., Hills, M., Mallon, E., Watters, A., Cooke, T., Paish, C., Wencyk, P., et al. (2003) · The Journal of Pathology · doi:10.1002/path.1313 · Cited by 231
Self-citationDybdal, N., Leiberman, G., Anderson, S., McCune, B., Bajamonde, A., Cohen, R. L., Mass, R. D., Sanders, C., & Press, M. F. (2005) · Breast Cancer Research and Treatment · doi:10.1007/s10549-004-6275-8 · Cited by 216
Self-citationPerez, E. A., Roche, P. C., Jenkins, R. B., Reynolds, C. A., Halling, K. C., Ingle, J. N., & Wold, L. E. (2002) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)62329-x · Cited by 214
Self-citationHER2 Testing in Breast Cancer: NCCN Task Force Report and Recommendations
Carlson, R. W., Moench, S. J., Hammond, M. E. H., Perez, E. A., Burstein, H. J., Allred, D. C., Vogel, C. L., Goldstein, L. J., Somlo, G., Gradishar, W. J., et al. (2006) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2006.2003 · Cited by 205
Self-citationIsola, J., Tanner, M., Forsyth, A., Cooke, T. G., Watters, A. D., & Bartlett, J. M. S. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0428-03 · Cited by 181
Best Practice No 176: Updated recommendations for HER2 testing in the UK
Ellis, I. O., Bartlett, J., Dowsett, M., Humphreys, S., Jasani, B., Miller, K., Pinder, S. E., Rhodes, A., & Walker, R. (2004) · Journal of Clinical Pathology · doi:10.1136/jcp.2003.007724 · Cited by 177
Self-citationHicks, D. G., & Tubbs, R. R. (2005) · Human Pathology · doi:10.1016/j.humpath.2004.11.010 · Cited by 173
Self-citationHER-2/neu Gene Amplification and Response to Paclitaxel in Patients With Metastatic Breast Cancer
Konecny, G., Thomssen, C., Lück, H., Untch, M., Wang, H.-J., Kuhn, W. C., Eidtmann, H., Bois, A. D., Olbricht, S., Steinfeld, D., et al. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh198 · Cited by 156
Self-citationMénard, S., Valagussa, P., Pilotti, S., Gianni, L., Biganzoli, E. M., Boracchi, P., Tomasic, G., Casalini, P., Marubini, E., COLNAGHI, M. I., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.2.329 · Cited by 149
Wang, S., Saboorian, M. H., Frenkel, E. P., Haley, B., Siddiqui, M. T., Gokaslan, S. T., Wians, F. H., Hynan, L. S., & Ashfaq, R. (2001) · American Journal of Clinical Pathology · doi:10.1309/tmuw-g4wb-lxj2-fudn · Cited by 137
Downs-Kelly, E. P., Yoder, B. J., Stoler, M. H., Tubbs, R. R., Skacel, M., Grogan, T. M., Roche, P. C., & Hicks, D. G. (2005) · The American Journal of Surgical Pathology · doi:10.1097/01.pas.0000165528.78945.95 · Cited by 119
Self-citationZarbo, R. J., Jones, B. A., Friedberg, R. C., Valenstein, P. N., Renner, S. W., Schifman, R. B., Walsh, M. K., & Howanitz, P. J. (2002) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2002-126-1036-qt · Cited by 115
Hanna, W. M., & Kwok, K. (2006) · Modern Pathology · doi:10.1038/modpathol.3800555 · Cited by 110
Self-citationPolysomy 17 in HER-2/neu Status Elaboration in Breast Cancer: Effect on Daily Practice
Ma, Y., Lespagnard, L., Durbecq, V., Paesmans, M., Desmedt, C., Gomez-Galdón, M., Veys, I., Cardoso, F., Sotiriou, C. P., Leo, A. D., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2256 · Cited by 108
Concordance Between Central and Local Laboratory HER2 Testing from a Community-Based Clinical Study
Reddy, J. C., Reimann, J. D., Anderson, S. M., & Klein, P. M. (2006) · Clinical Breast Cancer · doi:10.3816/cbc.2006.n.025 · Cited by 107
Enhanced Accuracy and Reliability of HER-2/neu Immunohistochemical Scoring Using Digital Microscopy
Bloom, K., & Harrington, D. S. (2004) · American Journal of Clinical Pathology · doi:10.1309/y73u-8x72-b68t-mgh5 · Cited by 106
Cardoso, F., Durbecq, V., Larsimont, D., Paesmans, M., Leroy, J., Rouas, G., Sotiriou, C. P., Renard, N., Richard, V., Piccart, M. J., et al. (2004) · International Journal of Oncology · doi:10.3892/ijo.24.1.201 · Cited by 94
Breast Cancer Clinical Practice Guidelines in Oncology
Carlson, R. W., Anderson, B. O., Burstein, H. J., Cox, C. E., Edge, S. B., Farrar, W. B., Goldstein, L. J., Gradishar, W. J., Hayes, D. F., Hudis, C. A., et al. (2005) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2005.0015 · Cited by 77
Self-citationClinical Laboratory Assays for HER-2/ neu Amplification and Overexpression
(2002) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2002-126-0803-clafhn · Cited by 74
Lago, L. D., Durbecq, V., Desmedt, C., Salgado, R., Verjat, T., Lespagnard, L., Ma, Y., Veys, I., Leo, A. D., Sotiriou, C. P., et al. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0129 · Cited by 73
Hammond, M. E. H., & Taube, S. E. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.32896 · Cited by 64
Self-citationComparative Assays for the HER-2/neu Oncogene Status in Breast Cancer
Vera-Román, J. M., & Rubio-Martínez, L. A. (2004) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2004-128-627-caftno · Cited by 62
Heart of Darkness: The Downside of Trastuzumab
Hayes, D. F., & Picard, M. H. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.5143 · Cited by 61
Self-citationFitzgibbons, P. L., Murphy, D. A., Dorfman, D. M., Roche, P. C., & Tubbs, R. R. (2006) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2006-130-1440-icoitf · Cited by 44
Self-citationPerez, E. A., Suman, V. J., Davidson, N. E., Martino, S., Kaufman, P. A., Lingle, W. L., Flynn, P. J., Ingle, J. N., Visscher, D. W., & Jenkins, R. B. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.14_suppl.567 · Cited by 20
Self-citationDAVIES, J. K., Taussig, D. C., Oakervee, H. E., Davies, A. J., Agrawal, S. G., Gribben, J. G., Lister, T. A., & Cavenagh, J. D. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.7281 · Cited by 19
Cited by
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Hammond, M. E. H., Hayes, D. F., Dowsett, M., Allred, D. C., Hagerty, K. L., Badve, S., Fitzgibbons, P. L., Francis, G., Goldstein, N. S., Hayes, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.6529 · Cited by 4,213
Self-citationWolff, A. C., Hammond, M. E. H., Hicks, D. G., Dowsett, M., McShane, L. M., Allison, K. H., Allred, D. C., Bartlett, J. M. S., Bilous, M., Fitzgibbons, P., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.9984 · Cited by 4,030
Self-citationGoldhirsch, A., Wood, W. C., Coates, A. S., Gelber, R. D., Thürlimann, B., & Senn, H.-J. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr304 · Cited by 3,836
Pembrolizumab for Early Triple-Negative Breast Cancer
Schmid, P., Cortes, J., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., Denkert, C., Park, Y. H., Hui, R., Harbeck, N., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1910549 · Cited by 3,270
Metadata
- Authors
- Wolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Langer, A., McShane, L. M., Paik, S., Pegram, M. D., Perez, E. A., Press, M. F., Rhodes, A., Sturgeon, C., Taube, S. E., Tubbs, R., Vance, G. H., van de Vijver, M., Wheeler, T. M., & Hayes, D. F.
- Venue
- Journal of Clinical Oncology
- Published
- 2007-01-01
- Volume
- 25
- Issue
- 1
- Pages
- 118-145
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2130900820
- Cited by
- 4,434
- References
- 57
- FWCI
- 80.61
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.